NR4A1 and breast carcinoma: While the standard 20 mg/day dose has demonstrated robust efficacy in reducing the incidence of hormone receptor–positive breast cancer, its broader adoption in the primary prevention setting has been hampered by concerns regarding safety, particularly the risks of thromboembolic events, endometrial cancer, vasomotor symptoms, and ocular toxicities in postmenopausal women [24,30,39].